BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
Status:
Terminated
Trial end date:
2018-11-16
Target enrollment:
Participant gender:
Summary
The primary goal of this Brown University Oncology Research Group is to determine that a safe
dose of BYL719 can be administered with capecitabine and radiation in patients with rectal
cancer. Therefore, the threshold of success for this phase I study is to establish safety.
Phase:
Phase 1
Details
Lead Sponsor:
howard safran
Collaborators:
Brown University Lifespan Novartis Pharmaceuticals Corporation (Financial supporter)